Chinese Journal of Dermatology ›› 2022, Vol. 55 ›› Issue (7): 622-628.doi: 10.35541/cjd.20220072
• Perspective • Previous Articles Next Articles
Jian Zhe, Zhang Jia
Received:
2022-01-26
Revised:
2022-05-25
Online:
2022-07-15
Published:
2022-07-05
Contact:
Zhang Jia
E-mail:362014063@qq.com
Supported by:
Jian Zhe, Zhang Jia. Research progress and thinking in mouse models of vitiligo-like depigmentation[J]. Chinese Journal of Dermatology, 2022, 55(7): 622-628.doi:10.35541/cjd.20220072
[1] | Ezzedine K, Eleftheriadou V, Whitton M, et al. Vitiligo[J]. Lancet, 2015,386(9988):74⁃84. doi: 10.1016/S0140⁃6736(14)60763⁃7. |
[2] | Tokura Y, Fujiyama T, Ikeya S, et al. Biochemical, cytological, and immunological mechanisms of rhododendrol⁃induced leukoderma[J]. J Dermatol Sci, 2015,77(3):146⁃149. doi: 10. 1016/j.jdermsci.2015.02.001. |
[3] | Abe Y, Okamura K, Kawaguchi M, et al. Rhododenol⁃induced leukoderma in a mouse model mimicking Japanese skin[J]. J Dermatol Sci, 2016,81(1):35⁃43. doi: 10.1016/j.jdermsci.2015. 10.011. |
[4] | Kunisada T, Lu SZ, Yoshida H, et al. Murine cutaneous mastocytosis and epidermal melanocytosis induced by keratinocyte expression of transgenic stem cell factor[J]. J Exp Med, 1998,187(10):1565⁃1573. doi: 10.1084/jem.187.10.1565. |
[5] | Ito S, Okura M, Nakanishi Y, et al. Tyrosinase⁃catalyzed metabolism of rhododendrol (RD) in B16 melanoma cells: production of RD⁃pheomelanin and covalent binding with thiol proteins[J]. Pigment Cell Melanoma Res, 2015,28(3):295⁃306. doi: 10.1111/pcmr.12363. |
[6] | Hayashi M, Okamura K, Abe Y, et al. Janus kinase inhibitor tofacitinib does not facilitate the repigmentation in mouse model of rhododendrol⁃induced vitiligo[J]. J Dermatol, 2019,46(6):548⁃550. doi: 10.1111/1346⁃8138.14879. |
[7] | Tsutsumi R, Sugita K, Abe Y, et al. Leukoderma induced by rhododendrol is different from leukoderma of vitiligo in pathogenesis: a novel comparative morphological study[J]. J Cutan Pathol, 2019,46(2):123⁃129. doi: 10.1111/cup.13396. |
[8] | Zhu Y, Wang S, Xu A. A mouse model of vitiligo induced by monobenzone[J]. Exp Dermatol, 2013,22(7):499⁃501. doi: 10.1111/exd.12184. |
[9] | van den Boorn JG, Konijnenberg D, Tjin EP, et al. Effective melanoma immunotherapy in mice by the skin⁃depigmenting agent monobenzone and the adjuvants imiquimod and CpG[J/OL]. PLoS One, 2010,5(5):e10626. doi: 10.1371/journal.pone.0010626. |
[10] | Westerhof W, Manini P, Napolitano A, et al. The haptenation theory of vitiligo and melanoma rejection: a close⁃up[J]. Exp Dermatol, 2011,20(2):92⁃96. doi: 10.1111/j.1600⁃0625.2010. 01200.x. |
[11] | van den Boorn JG, Melief CJ, Luiten RM. Monobenzone⁃induced depigmentation: from enzymatic blockade to autoimmunity[J]. Pigment Cell Melanoma Res, 2011,24(4):673⁃679. doi: 10.1111/j.1755⁃148X.2011.00878.x. |
[12] | van den Boorn JG, Picavet DI, van Swieten PF, et al. Skin⁃depigmenting agent monobenzone induces potent T⁃cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy[J]. J Invest Dermatol, 2011,131(6):1240⁃1251. doi: 10.1038/jid.2011.16. |
[13] | Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self⁃reactive CD8+ T cells[J]. J Exp Med, 2003,198(4):569⁃580. doi: 10.1084/jem.20030590. |
[14] | Harris JE. Chemical⁃induced vitiligo[J]. Dermatol Clin, 2017,35(2):151⁃161. doi: 10.1016/j.det.2016.11.006. |
[15] | Mansourpour H, Ziari K, Motamedi SK, et al. Therapeutic effects of iNOS inhibition against vitiligo in an animal model[J]. Eur J Transl Myol, 2019,29(3):8383. doi: 10.4081/ejtm.2019.8383. |
[16] | 祝逸平, 王遂泉, 李阳, 等. 局部针刺对莫诺苯宗诱导C57BL/6小鼠白癜风样模型的影响[J]. 中华皮肤科杂志, 2014,47(1):26⁃29. doi: 10.3760/cma.j.issn.0412⁃4030.2014.01.008. |
[17] | 李情, 祝逸平, 许爱娥. 茶多酚、吡美莫司、他克莫司外用对莫诺苯宗诱导白癜风样模型小鼠的疗效比较[J]. 中华皮肤科杂志, 2015,48(1):41⁃44. doi: 10.3760/cma.j.issn.0412⁃4030. 2015.01.014. |
[18] | Finkelstein SE, Heimann DM, Klebanoff CA, et al. Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer[J]. J Leukoc Biol, 2004,76(2):333⁃337. doi: 10.1189/jlb.0304120. |
[19] | Overwijk WW, Tsung A, Irvine KR, et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"⁃reactive, tumoricidal T cells using high⁃affinity, altered peptide ligand[J]. J Exp Med, 1998,188(2):277⁃286. doi: 10.1084/jem.188. 2.277. |
[20] | Klebanoff CA, Finkelstein SE, Surman DR, et al. IL⁃15 enhances the in vivo antitumor activity of tumor⁃reactive CD8+ T cells[J]. Proc Natl Acad Sci U S A, 2004,101(7):1969⁃1974. doi: 10.1073/pnas.0307298101. |
[21] | Riding RL, Richmond JM, Harris JE. Mouse model for human vitiligo[J]. Curr Protoc Immunol, 2019,124(1):e63. doi: 10. 1002/cpim.63. |
[22] | Grichnik JM, Burch JA, Burchette J, et al. The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis[J]. J Invest Dermatol, 1998,111(2):233⁃238. doi: 10.1046/j.1523⁃1747.1998.00272.x. |
[23] | Wehrle⁃Haller B. The role of Kit⁃ligand in melanocyte development and epidermal homeostasis[J]. Pigment Cell Res, 2003,16(3):287⁃296. doi: 10.1034/j.1600⁃0749.2003.00055.x. |
[24] | Nishimura EK, Jordan SA, Oshima H, et al. Dominant role of the niche in melanocyte stem⁃cell fate determination[J]. Nature, 2002,416(6883):854⁃860. doi: 10.1038/416854a. |
[25] | Nishimura EK, Yoshida H, Kunisada T, et al. Regulation of E⁃ and P⁃cadherin expression correlated with melanocyte migration and diversification[J]. Dev Biol, 1999,215(2):155⁃166. doi: 10.1006/dbio.1999.9478. |
[26] | Lo JA, Kawakubo M, Juneja VR, et al. Epitope spreading toward wild⁃type melanocyte⁃lineage antigens rescues suboptimal immune checkpoint blockade responses[J]. Sci Transl Med, 2021,13(581): eabd8636. doi: 10.1126/scitranslmed.abd8636. |
[27] | Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab[J]. JAMA Dermatol, 2016,152(1):45⁃51. doi: 10.1001/jamadermatol.2015.2707. |
[28] | Herzberg B, Fisher DE. Metastatic melanoma and immunotherapy[J]. Clin Immunol, 2016,172:105⁃110. doi: 10. 1016/j.clim.2016.07.006. |
[29] | Turk MJ, Guevara⁃Patiño JA, Rizzuto GA, et al. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells[J]. J Exp Med, 2004,200(6):771⁃782. doi: 10.1084/jem.20041130. |
[30] | Xu Z, Chen D, Hu Y, et al. Anatomically distinct fibroblast subsets determine skin autoimmune patterns[J]. Nature, 2022,601(7891):118⁃124. doi: 10.1038/s41586⁃021⁃04221⁃8. |
[31] | Halprin KM. Epidermal "turnover time"⁃⁃a re⁃examination[J]. Br J Dermatol, 1972,86(1):14⁃19. doi: 10.1111/j.1365⁃2133. 1972.tb01886.x. |
[32] | Gregg RK, Nichols L, Chen Y, et al. Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase⁃specific TCR transgenic mice[J]. J Immunol, 2010,184(4):1909⁃1917. doi: 10.4049/jimmunol.0902778. |
[33] | Nichols LA, Chen Y, Colella TA, et al. Deletional self⁃tolerance to a melanocyte/melanoma antigen derived from tyrosinase is mediated by a radio⁃resistant cell in peripheral and mesenteric lymph nodes[J]. J Immunol, 2007,179(2):993⁃1003. doi: 10. 4049/jimmunol.179.2.993. |
[34] | Eby JM, Kang HK, Klarquist J, et al. Immune responses in a mouse model of vitiligo with spontaneous epidermal de⁃ and repigmentation[J]. Pigment Cell Melanoma Res, 2014,27(6):1075⁃1085. doi: 10.1111/pcmr.12284. |
[35] | Eby JM, Kang HK, Tully ST, et al. CCL22 to activate Treg migration and suppress depigmentation in vitiligo[J]. J Invest Dermatol, 2015,135(6):1574⁃1580. doi: 10.1038/jid.2015.26. |
[36] | Mehrotra S, Al⁃Khami AA, Klarquist J, et al. A coreceptor⁃independent transgenic human TCR mediates anti⁃tumor and anti⁃self immunity in mice[J]. J Immunol, 2012,189(4):1627⁃1638. doi: 10.4049/jimmunol.1103271. |
[37] | Oyarbide⁃Valencia K, van den Boorn JG, Denman CJ, et al. Therapeutic implications of autoimmune vitiligo T cells[J]. Autoimmun Rev, 2006,5(7):486⁃492. doi: 10.1016/j.autrev.2006. 03.012. |
[38] | Wang S, Zhou M, Lin F, et al. Interferon⁃γ induces senescence in normal human melanocytes[J/OL]. PLoS One, 2014,9(3):e93232. doi: 10.1371/journal.pone.0093232. |
[39] | Dell′anna ML, Cario⁃André M, Bellei B, et al. In vitro research on vitiligo: strategies, principles, methodological options and common pitfalls[J]. Exp Dermatol, 2012,21(7):490⁃496. doi: 10.1111/j.1600⁃0625.2012.01506.x. |
[1] | Li Baizhang, Kang Pan, Zhang Xiaoying, Zhu Guannan, Li Shuli, Li Chunying. Construction and validation of a risk prediction model for diabetes mellitus in patients with vitiligo [J]. Chinese Journal of Dermatology, 2022, 55(7): 576-582. |
[2] | Ainiwaer·Talifu, Xiong Cheng, Refuhati·Saimaiti, Yusufu·Maitinuer, Tuerxun·Wufuer, Akenmujiang·Aierken, Julaiti·Abuduwayiti, Maimaitiaili·Kade. Screening and analysis of differentially expressed genes in vitiligo using bioinformatics methods [J]. Chinese Journal of Dermatology, 2022, 55(5): 421-425. |
[3] | Fu Chao, Wu Jiaona, Lang Wenchao, Gao Fei, Niu Guiye, Bian Peiwen, Gao Minhong, Si Xiaoqing, Xin Linlin. Role of dermoscopy in assessing vitiligo activity [J]. Chinese Journal of Dermatology, 2022, 55(3): 268-271. |
[4] | Lei Jiehao, Hong Weisong, Lin Fuquan, Hu Wenting, Xu Ai′e. In vitro culture of melanocytes from segmental vitiligo-like nevus depigmentosus lesions and its clinical significance [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210350-e20210350. |
[5] | Luan Chao, Hu Yu, Chen Kun, Zhang Jiaan, Gu Heng, Zhang Ronglin, Zhang Xiaohua, Tian Panpan, Zhu Yan, Zhuang Chen, Huang Dan, Ju Mei. Efficacy and safety of 308-nm SQ light-emitting diode light and 308-nm excimer light in the treatment of facial vitiligo: a retrospective study [J]. Chinese Journal of Dermatology, 2022, 55(1): 16-19. |
[6] | Chen Yi, Song Xiuzu. Role of transient receptor potential channels in melanocytes and their related diseases [J]. Chinese Journal of Dermatology, 2022, 0(1): 20200958-e20200958. |
[7] | Ying Jieya, Xiang Wenzhong, Song Xiuzu. Metabolic syndrome and skin diseases [J]. Chinese Journal of Dermatology, 2021, 54(7): 642-645. |
[8] | Guo Lifang, Ge Yiping, Yang Yin, Lin Tong. Establishment and evaluation of an artificial intelligence model for the diagnosis of facial vitiligo [J]. Chinese Journal of Dermatology, 2021, 54(7): 586-589. |
[9] | Liao Zhikai, Lei Tiechi. Therapeutic trauma-induced repigmentation of vitiligo lesions: mechanisms and relevant clinical studies [J]. Chinese Journal of Dermatology, 2021, 54(3): 267-269. |
[10] | Xie Bo, Wei Xiaodong, Xu Ai′e, Lin Fuquan, Zhou Miaoni. Efficacy of systemic glucocorticoid treatment and its related factors in patients with progressive vitiligo [J]. Chinese Journal of Dermatology, 2021, 54(2): 139-144. |
[11] | Pigmentary Disorder Group, Combination of Traditional and Western Medicine Dermatology. Consensus on the diagnosis and treatment of vitiligo (2021 version) [J]. Chinese Journal of Dermatology, 2021, 54(2): 105-109. |
[12] | Zhou Miaoni, Lin Fuquan, Zhu Yiping, Jin Rong, Sheng Anqi, Xu Wen, Xu Ai′e . Role of folliculin in interferon-γ-mediated apoptosis of and chemokine secretion by melanocytes [J]. Chinese Journal of Dermatology, 2021, 54(10): 878-883. |
[13] | Lin Chen 修 艳燕 侯 晓媛 Wang Haoyang Xue-Chen CAO luyan luyanluyan. Clinical efficacy of narrow-band ultraviolet B irradiation around vitiliginous lesions in the treatment of refractory vitiligo [J]. Chinese Journal of Dermatology, 2021, 54(10): 851-855. |
[14] | Wu Xingang, Hong Weisong, Wei Xiaodong, Fu Lifang, Xu Ai′e. Therapeutic efficacy and safety of cultured autologous melanocyte transplantation for patients with non-segmental vitiligo complicated by autoimmune thyroid diseases: a clinical observation and long-term follow-up [J]. Chinese Journal of Dermatology, 2021, 54(10): 847-850. |
[15] | Jia Weixue, Li Chengrang. Comparison of Chinese and international guidelines and consensus for the diagnosis and treatment of vitiligo [J]. Chinese Journal of Dermatology, 2021, 0(1): 20201048-e20201048. |
|